Multi-omics profiling of collagen-induced arthritis mouse model reveals early metabolic dysregulation via SIRT1 axis

Lingzi Li¹, Janina Freitag¹, Christian Asbrand¹, Bogdan Munteanu², Bei-Tzu Wang², Ekaterina Zezina³, Michel Didier³, Gilbert Thill³, Corinne Rocher³, Matthias Herrmann¹ & Nadine Biesemann¹

Rheumatoid arthritis (RA) is characterized by joint infiltration of immune cells and synovial inflammation which leads to progressive disability. Current treatments improve the disease outcome, but the unmet medical need is still high. New discoveries over the last decade have revealed the major impact of cellular metabolism on immune cell functions. So far, a comprehensive understanding of metabolic changes during disease development, especially in the diseased microenvironment, is still limited. Therefore, we studied the longitudinal metabolic changes during the development of murine arthritis by integrating metabolomics and transcriptomics data. We identified an early change in macrophage pathways which was accompanied by oxidative stress, a drop in NAD+ level and induction of glucose transporters. We discovered inhibition of SIRT1, a NAD-dependent histone deacetylase and confirmed its dysregulation in human macrophages and synovial tissues of RA patients. Mining this database should enable the discovery of novel metabolic targets and therapy opportunities in RA.

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by infiltration of immune cells in joints, synovial hyperplasia, and joint damage. The etiology of RA is multifactorial, which involves risk factors of genetics and environment. As RA patients exhibit broad biological heterogeneity with varying clinical outcomes, the underlying molecular mechanism of RA onset and manifestation remains elusive by far. Deeper insights into the early stages of the disease are urgently needed to develop novel therapies that break the ceiling of efficacy of currently approved drugs.

Immunometabolism has emerged in the recent years as a potential mechanism central to the regulation of immune cells. Major aspects of metabolic reprogramming in pro-inflammatory immune cells include a switch to aerobic glycolysis to support rapid ATP production and nucleic acid synthesis. On the other hand, anti-inflammatory cells tend to rely on oxidative phosphorylation (OXPHOS) and fatty acid oxidation for efficient energy production to sustain longevity. There is growing evidence that metabolism plays a critical role in RA. Joints from RA patients have increased uptake of glucose, along with upregulation of glycolysis in macrophages and fibroblast-like synoviocytes (FLS). We have recently described induction of glycolytic genes and hypoxia-induced factor 1 alpha (HIF1A) after TNF-α (tumor necrosis factor alpha) stimulation of RA-FLS. Furthermore, excessive production of reactive oxygen species (ROS) and oxidative stress are implicated in the pathogenesis of arthritis joints. However, little is known about the impact of cellular metabolism in the evolution of RA pathogenesis.

Here we present a multi-omics approach to fill the knowledge gap and to provide a comprehensive overview on the longitudinal metabolic changes over the course of RA progression. We utilized the collagen-induced arthritis (CIA) mouse model, to reflect pathological features of rheumatoid arthritis. The induction of disease in CIA mice was with Type II collagen, which is a major protein in cartilage. Antibody and T cell responses to Type II collagen have been detected in both CIA mice and RA patients. The histological features of CIA mouse joints, including synovial tissue hyperplasia, lymphocyte filtration and pannus formation, correspond with the clinical onset of human RA. We combined bulk RNA-seq and tissue MALDI-MS imaging on CIA mouse
paws with metabolomics on CIA plasma, and back-translated our findings with clinical data from different RA disease stages. In addition, the longitudinal plasma metabolomics dataset offers a resource for mining early RA biomarkers. Finally, we identified SIRT1 axis in macrophages as a potential driver of early RA disease stages.

Results

Comprehensive characterization of arthritis progression in CIA mice. CIA was induced by immunizations with Type II collagen in Complete Freund's adjuvant (CFA) at day 0, and boosted with Type II collagen in Incomplete Freund's adjuvant (IFA) at day 21. Arthritis development was followed over 10 weeks and mice were sacrificed for tissue collection at eight different time points covering early, middle and late disease stages (Fig. 1a). Evaluation of arthritis was conducted by scoring based on the swelling and redness of the paws (Fig. 1b). Score 0 indicated no visible sign of inflammation. The first sign of paw inflammation (arthritis score > 0) occurred 2 weeks after the 1st immunization and the disease severity progressed over the course of the whole study (Fig. 1c). Variation in arthritis severity was observed (Fig. 1d), matching to previous studies on CIA mouse models.21,22 The arthritis manifestation was accompanied by splenomegaly that became evident from week 2 on (Fig. 1e), which indicates hyperplasia of immune cells. Plasma pro-inflammatory cytokine TNF-α (Fig. 1f) revealed a partial separation of the CIA samples from the control samples starting from week 3 (Fig. 2a). The UPLC-MS/MS analysis detected 929 metabolites (Fig. 2b) and surprisingly, there were already over 100 significantly altered metabolites at day 2 (Fig. 2c). A large share of changes in the early time points came from peptides, energy metabolites, cofactors and vitamins (Fig. 2d). Furthermore, peptides and energy metabolites tended to be more upregulated than downregulated, whereas cofactors and vitamins tended to be more down-regulated (Fig. 2e).

We then proceeded to investigate the metabolite molecules that drove these changes (Fig. 2f). Of the peptides that are significantly altered in at least 2 time points, the group of gamma-glutamyl amino acids are significantly increased in early time points (day 2 and week 2, Fig. 2f). These early perturbations persisted until the last time point (week 10) for gamma-glutamylglutamate, gamma-glutamyltyrosine and gamma-glutamylcitrulline (Fig. 2f). The elevated plasma gamma-glutamyl amino acids are a sign of increased activities in the gamma-glutamyl cycle,24 which is essential for metabolism of the antioxidant glutathione and re-utilization of amino acids. Gamma-glutamyl transferase (GGT) on the cell membranes degrades extracellular glutathione into dipeptide cysteinyl-glycine and transfers gamma-glutamyl moiety to amino acids to form gamma-glutamyl amino acids. These are taken up by the cells and re-utilized as precursors for the intracellular synthesis of glutathione and proteins to support cellular functions.25 Glutathione is the central metabolite in this pathway and has multiple functions including defense against oxidative stress, redox signaling and cell proliferation.

The evidence of dysregulated redox signaling was further strengthened by early changes in nicotinamide (Fig. 2g). Among the energy metabolites and the related cofactors, nicotinamide and itaconate had persistent perturbations in all 8 time points from day 2 until week 10 (Fig. 2g). Nicotinamide belongs to the classical NAD+ salvage pathway, where nicotinamide is recycled back into NAD+27. Besides, NAD+ can also be converted from nicotinic acid through the Preiss–Handler pathway.28,29 We observed reduction in nicotinamide and nicotinamide N-oxide in the early time point at day 2 (Fig. 2g). Other nicotinamide metabolites (1-methyl-2-pyridone-5-carboxamide) and precursors of NAD+ in the Preiss–Handler pathway nicotine ribonucleoside and trigonelline) began to show significant reduction at later time points (week 3–4). Interestingly, the level of a precursor for the NAD+ de novo biosynthesis, quinolinic acid, started to rise from week 3. Although the current plasma untargeted metabolomics analysis did not profile NAD+, we reasoned that the plasma NAD+ level is probably depleted in CIA mice in early arthritis, resulting in decreased levels of nicotinamide metabolites in its salvage pathway.

The robust surge in itaconate from day 2 onwards pointed towards an early shift in the tricarboxylic acid (TCA) cycle (Fig. 2g). Iaconate is produced by diverting cis-aconitate away from the TCA cycle upon pro-inflammatory macrophage activation.30 This also explains the observation that the downstream molecules of TCA cycle, isocitrate and malate, decreased in plasma of CIA mice. In addition, these changes were in parallel to early rises in plasma TNF-α (Fig. 1f) which is mainly secreted from macrophages. This result supports the hypothesis that activation of pro-inflammatory macrophage plays a key role in early pathogenesis of RA.

Transcriptome analysis identified SIRT1 as an upstream regulator in mouse arthritis. Next, we performed bulk RNA-seq on the paw homogenates to study gene expression over disease progression. Paw transcriptome PCA showed a gradual separation between samples as the arthritis score increased (Fig. 3a). The samples from visually healthy paws (arthritis score = 0) tended to cluster on the lower left part of the PCA plot, whereas inflamed samples tended to move to the upper right part as the arthritis scores increased. When comparing transcriptomes between different time points (Fig. 3b), we saw a partial separation of the CIA samples from the controls starting from week 3, matching the pattern on the PCA plot of CIA plasma metabolome
**Figure 1.** Arthritis progression in CIA mice. (a) Experimental scheme. (b) Representative mouse paws with corresponding arthritis scores. (c) Evolution of arthritis severity by scores (sum of 4 paws, plotted as mean ± SEM). (d) Arthritis severity at each sacrifice time point per mouse subject. (e) Spleen weight measured at each sacrifice time point. (f) Plasma TNF-α concentration. (g) Plasma CXCL1 concentration. (h) Plasma CCL5 concentration. The cytokines and chemokines were measured by mouse magnetic Luminex assays. The dots on the boxplots represent individual mouse samples. At each time point, the sample size for controls is ≥ 5 and the sample size for CIA is ≥ 16. The color of each dot represents the arthritis score of the mouse (sum of 4 paws). Two-tail Welch t tests were performed (p < 0.05*, p < 0.01**, p < 0.001***).
PCA on plasma metabolome

- **Coverage of metabolite class groups**
  - PCA: 23.8% variance
  - Treatment: ORT, CA
  - Time: 2 days, 3 weeks, 4 weeks, 6 weeks, 7 weeks, 8 weeks, 10 weeks

- **Number of significant metabolites**
  - Direction: Up, Down
  - FDR < 0.05 and logFoldChange > 0.5

- **Normalized fraction of significant metabolites per group**
  - Amino Acid, Peptide, Carbohydrate, Energy, Lipid, Nucleotide, Cofactors and Vitamins, Xenobiotics, Partially Characterized Molecules, N/A

- **Peptides significant at >= 2 time points**
  - log2(FoldChange)

- **Energy and related cofactors significant at >= 2 time points**
  - log10(FDR)

- **Percentage of significant metabolites per group**
  - Up, Down
Multi-omics factor analysis identified factors correlating with arthritis severity. Combined analysis of omics datasets has dramatically increased both, our understanding and the validation of pathways and targets. Therefore, we assembled the transcriptome data from paws and the metabolomics data from plasma from in total 171 overlapping mice and run multi-omics factor analysis (MOFA). MOFA is an unsupervised method which infers a set of low-dimensional data representations, factors, which drive the major variations among the data. MOFA identified 6 factors (Fig. 3b), based on the criterion that a factor should account for > 2% of the variance in at least one omics dataset. Among these factors, Factor 1 and 2 were mainly active in the transcriptome data. In contrast, Factor 3 was mainly specific to metabolomics data. Cumulatively, the 6 factors explained nearly 20% of variation in metabolomics data and 70% of transcriptome data (Fig. S1).
**a** PCA on paw transcriptome (color by score)

**b** PCA on paw transcriptome (color by time point)

**c** Number of differentially expressed genes

**d** Gene set enrichment analysis

**e** IPA upstream regulator analysis

- **PCA on paw transcriptome (color by score)**
  - PC1: 34% variance
  - PC2: 19% variance
  - Treatment: Ctrl, CIA
  - Paw score: 0, 1, 2, 3

- **PCA on paw transcriptome (color by time point)**
  - PC1: 34% variance
  - PC2: 19% variance
  - Treatment: Ctrl, CIA
  - Time: 2 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 7 weeks, 8 weeks, 10 weeks

- **Number of differentially expressed genes**
  - FDR < 0.05 and \( \log2(\text{FoldChange}) = 0.5 \)
  - Direction: Up, Down

- **Gene set enrichment analysis**
  - Gene Ontology biological process
  - Glycolytic process
  - Tricarboxylic acid cycle
  - Oxidative phosphorylation
  - Respiratory electron transport chain
  - Nitrile biosynthetic process
  - Reactive oxygen species metabolic process
  - Toll-like receptor signaling pathway
  - Neutrophil activation
  - Macrophage differentiation
  - Leukocyte migration
  - Lymphocyte migration

- **IPA upstream regulator analysis**
  - Z-score
  - Direction: Depleted, Enriched
  - \(-\log10(\text{FDR})\): 2, 4, 6, 8
  - FDR < 0.05
  - No, Yes
TLR4 signaling leads to accumulation of HIF1A40. Previous studies have linked activation of HIF1A closely to pathway and innate immunity were enriched. Toll-like receptor 4 (TLR4) is required for LPS recognition and port chain were depleted upon LPS stimulation, whereas gene sets of ROS metabolism, toll-like receptor signaling results as the analysis on CIA transcriptome (Fig. 6c). The gene sets of OXPHOS and respiratory electron trans-

We wondered whether these factors would be able to describe the different stages of disease or disease scores. Factor 1 clearly separated the four groups of paw arthritis scores, which suggests that Factor 1 is able to represent the arthritis severity of mice (Fig. 5c). To investigate the aetiology of Factor 1, we plotted the weights of the top mRNA features on Factor 1 (Fig. 5d). The neutrophil-recruiting chemokine CXCL538 and the joint-degrading matrix metalloproteinases (MMPs)39 were assigned the highest positive weights in Factor 1, suggesting that Factor 1 is positively associated with neutrophil activation and joint damage. To further understand the molecular functions of Factor 1, we performed gene set enrichment analysis on the feature weights of mRNA in Factor 1 (Fig. 5e). We found enrichment in the gene sets of ROS production and toll-like receptor signaling pathways, and depletion in the gene sets of OXPHOS and respiratory electron transport chain, which are in line with the analysis results on bulk RNA-seq of mouse paws. Taken together, MOFA results suggest that Factor 1 serves a representa-

Pro-inflammatory macrophage transcriptome changes partially overlapped with early CIA transcriptome changes. The highest elevated energy metabolite in CIA mouse plasma was itaconate (Fig. 2g), a signature metabolite of pro-inflammatory macrophage activation30. In addition, we observed signif-
icant upregulations in several innate immunity pathways and innate upstream regulators like LPS (Fig. 3d,e). We therefore hypothesized that a large proportion of metabolic programming in arthritis inflammation could be driven by macrophages. We next investigated the transcriptome by bulk RNA-seq on human primary mono-
cyte-derived macrophages after LPS stimulation. PCA on macrophage transcriptome showed a clear separation between LPS-stimulated and unstimulated macrophages (Fig. 6a). We then compared the significant differentially expressed genes between CIA paws at week 3 and LPS-stimulated human macrophages (Fig. 6b). Although the overall overlap was limited due to the drastic changes on macrophages stimulated in an in vitro setting, we found 254 shared upregulated genes, which reflects ~ 30% (254/838) of significantly differentially upregulated genes in CIA paws at week 3.

Gene set enrichment analysis on LPS-stimulated human macrophage transcriptome also yielded similar results as the analysis on CIA transcriptome (Fig. 6c). The gene sets of OXPHOS and respiratory electron transport chain were depleted upon LPS stimulation, whereas gene sets of ROS metabolism, toll-like receptor signaling pathway and innate immunity were enriched. Toll-like receptor 4 (TLR4) is required for LPS recognition and TLR4 signaling leads to accumulation of HIF1A40. Previous studies have linked activation of HIF1A closely to ROS generation and increase of glycolytic activity45. Upstream regulator analysis using IPA on LPS-stimulated macrophages was also generally in line with the analysis on CIA paws, where LPS, IFNG, TNF and NFXB were predicted to be activated (Fig. 6d). Furthermore, SIRT1 (Fig. 6d) was predicted to be inhibited, with no significant change at its transcriptional level (Fig. S3). Overall, we observed consistent metabolic and immunological changes on transcriptome level between CIA paws and LPS-stimulated macrophages.

Metabolic dysregulation confirmed by transcriptome changes in various stages of RA patient disease progression. To validate the findings on CIA paws in a context of human RA, we looked into a published RNA-seq dataset (GSE89408)42 on synovium biopsies from healthy humans and arthritis patients at different disease stages. The pathogenesis of human RA (Fig. 7a) originates from asymptomatic autoimmunity, which manifests into arthralgia with nonspecific joint symptoms, further progresses to UA with clinical syno-
vitis, and subsequently advances into the early stage of RA. PCA on human synovium transcriptome revealed clear separation between the healthy group and the clinically symptomatic groups (Fig. 7b). In contrast, the early RA group overlapped with the UA group and partially overlapped with the arthralgia group in PCA. This suggests that although there is a clear divergence between the healthy and the diseased, much less differentiation exists between the different disease stages. We performed the differential gene expression test (Fig. 7c) and then compared the significant differentially upregulated genes between CIA paws at week 3 and human synovium (Fig. 7d). We found 310 shared upregulated genes between CIA paws at week 3 and early RA human synovium, which reflects ~ 37% (310/838) of significant upregulated genes in CIA paws at week 3. In addition, the overlap was most pronounced with early RA (Fig. 7d) in contrast to the other human RA phenotypes. It should be men-
tioned though, that the human RA study revealed a huge amount of transcript changes which are only partially seen in mouse CIA (Fig. 7d).

Despite these limitations, gene set enrichment analysis on human synovium transcriptome was also largely in line with the analysis on CIA transcriptome (Fig. 7e). The gene sets of OXPHOS and respiratory electron transport chain were depleted while the gene sets of ROS metabolism enriched. In addition, we also observed an
enrichment of gene sets of innate immunity, including toll-like receptor signaling pathway, neutrophil activation, and leukocyte migration. Furthermore, upstream regulator analysis using IPA on human synovium biopsies gave rise to similar predictions as the analysis on CIA paws (Fig. 7f, Supplementary Table 2), although SIRT1 signaling was—despite being significant—to a lower extent inhibited. Comparing the in vitro macrophage, human RA and mouse CIA studies, we identified the following consistent upstream regulators: LPS, IFNG, TNF and NFκB were upregulated, while Irgm1 and SIRT1 were inhibited across the studies. Overall, we were able to confirm and translate the metabolic reprogramming in CIA paws with the early human RA synovium RNA-seq results.

Consistent changes in oxidative stress, glycolysis and NFkB targets. To query the metabolic reprogramming at individual gene level, we looked into the changes of major metabolic and innate immunity genes in the significantly altered pathways identified via the gene set enrichment analysis. NFkB mediated pro-inflammatory molecules in the immune activation, such as IL6 and IL1B, showed consistent increase of gene expression (Fig. 8a). In line with the increased ROS production, we observed significant upregulation of myelop-
Multi-omics data integration by MOFA model

Variance explained by individual factors for each omics study

Factor values per mouse sample

Absolute weights of top mRNA features in Factor 1

Gene set enrichment analysis on feature weights

Figure 5. Multi-omics data integration identifies ROS as disease-correlated factor. (a) Overview of MOFA model. MOFA[^1] is an unsupervised method for integrating multi-omics data. In this study, MOFA decomposes the data matrices of metabolomics and transcriptomics with co-occurring samples into a weight matrix for each omics data and a matrix of factors for each sample. "Features" denote metabolites in metabolomics data, or mRNA in transcriptome data. Visualization of sample groups by factor values can identify factors associated with disease phenotypes. (b) Proportion of total variance (Var.) explained by individual factors for each omics experiment. (c) Visualization of samples using Factors 1, 2 and 3. The dots on violin plots represent mouse subjects. The colors denote the arthritis scores of the right hind paws. One-way ANOVA was used to assess if there is any significant difference among the subjects in the 4 score groups (p < 0.05*, p < 0.01**, p < 0.001***). (d) Absolute weights of the top features of Factors 1 in transcriptome data. (e) Gene set enrichment analysis on the feature weights of mRNA in Factor 1 (FDR < 0.05).
**Figure 6.** Transcriptional profiling of LPS-stimulated human macrophages partially overlaps to early transcript changes in mouse CIA. Bulk RNA-seq analysis of human monocyte-derived macrophages from four human donors. Stimulation was done with 50 ng/ml LPS for 24 h. (a) PCA score plot with four samples of human macrophages before and after LPS stimulation. (b) Overlap of significant differentially expressed genes between CIA paws at week 3 and LPS-stimulated macrophages. The Wald test in DESeq2 was performed for statistical analysis on macrophage dataset and LPS-stimulated samples were compared to the unstimulated. (c) Enriched or depleted Gene Ontology biological process gene sets. (d) Top 20 activated and top 20 inhibited upstream regulators from analysis by IPA. Only upstream regulators with Benjamini–Hochberg (B–H) adjusted p-values < 0.05 were shown with z-scores on a color gradient (activated: pink, inhibited: green).
availability of amino acids. Low NAD+ level causes inhibition of SIRT1, which results in accumulation of HIF1A
OXPHOS that slows regeneration of NAD+ by Complex I, increased ROS production and increased intracellular
activation of these innate immune cells is accompanied by increased glycolysis that consumes NAD+, decreased
metabolites56. The identification of itaconate as a potential arthritis biomarker was also reported in the serum/
resveratrol, an unspecific SIRT1 activator, enhanced anti-inflammatory M2 and blocked pro-inflammatory M1
(Figs. 3e, 6d, 7f) predicted that the key metabolic sensor, SIRT1, was inhibited, while its downstream target NFκB
cal role in the early pathology in CIA paws. Interestingly, in line with this finding (Fig. 8b,c). MPO is involved in ROS generation43 and is required for neutrophil extracellular trap (NET) formation45. NETs have been implicated in microbial defense and served as a source of autoantigens in RA56. In addition, NADPH oxidase is critical for ROS production in neutrophils and macrophages49.

The NAD-dependent SIRT1 also directly regulates cellular metabolism via inhibiting the key transcription factor HIF1A by deacetylation47. HIF1A, was significantly upregulated in LPS-stimulated human macrophages and synovium biopsies of RA patients (Fig. 8b,c). HIF1A is one of the mediators of SIRT1 regulating immune-metabolism by promoting expression of genes involved in glycolysis48. Upon examining the differential expression of glycolytic genes, we observed consistent upregulation in glucose transporters GLUT3 (SLC2A3) and GLUT6 (SLC2A6, Fig. 8a–c) in all RNA-seq datasets. We also observed increased protein levels of SIRT1 target c-Myc49 and lactate/pyruvate transporter MCT1 in CIA paws at early stages (Figs. S4, S5), strengthening our hypothesis on increased glycolysis.

Increased glycolysis and a broken TCA cycle are characteristics of pro-inflammatory macrophages. ACOD1 encodes an itaconate-producing enzyme, shifting TCA cycle towards itaconate production in pro-inflammatory macrophages50. ACOD1, was also significantly upregulated in CIA paws and LPS-stimulated human macrophages (Fig. 8a,b). ACOD1 expression in human synovium RNA-seq dataset was too low and therefore it was filtered out before differential gene expression analysis (Fig. 8c).

Discussion

Understanding the pathogenesis of RA is essential for development of new therapeutics. However, few studies have systematically examined the early metabolic changes in arthritis. Here, we analyzed the transcriptome and metabolome to provide a time-resolved comprehensive overview on the arthritis progression in CIA mice. We then used an unsupervised multi-omics factor analysis method to identify the important metabolic processes in etiology of RA development. Furthermore, we validated the major findings of the CIA study with two human datasets, including LPS-stimulated macrophages and synovium biopsies of RA patients.

The onset of clinical RA is preceded by a phase of asymptomatic autoimmunity where innate immunity plays a key role in disease progression2,51. In human RA synovium, neutrophils and macrophages are the highly abundant cell types52–54 and the number of synovial macrophages may predict joint destruction55. Furthermore, activation of innate immune cells was also observed in synovium biopsies from treatment-naïve early RA5. In our study, we observed a substantial increase of the pro-inflammatory macrophage activation marker itaconate in plasma and neutrophil activation marker MPO in the paws, just 2 days after the first immunization. These early innate changes were confirmed by both gene set enrichment and upstream regulator analysis. In addition, 30–37% of the CIA gene differential expression could be explained by the transcriptome changes of LPS-stimulated human macrophages and human synovium of early RA. We therefore hypothesize that innate immune cells have a critical role in the early pathology in CIA paws.

The observed metabolic changes were also in alignment with innate immune cell activation and infiltration. We report that metabolic changes at both gene expression and metabolite levels occurred already at the asymptomatic stages of the CIA mouse model (day 2 and week 2). There, gamma-glutamyl amino acids were significantly increased and the NAD+ precursor in salvage pathway, nicotinamide, was depleted in CIA plasma. In addition, MALDI-MS imaging confirmed the depletion of NAD+ in CIA paws. Interestingly, in line with our findings, the metabolite of nicotinamide, 1-methyl nicotinamide, was significantly decreased in plasma of active RA patients56. Furthermore, plasma of RA patients showed dysregulated glycolysis, TCA and amino acid metabolites57. The identification of itaconate as a potential arthritis biomarker was also reported in the serum/urine of Tg197 arthritis mouse model45. Recently, itaconate was identified in an unbiased metabolomics study as early biomarker in RA58. This highlights the translational relevance of our longitudinal study and hopefully encourages the validation of some novel described metabolites like gamma-glutamyl amino acids in the future.

Direct comparison of mouse and human datasets in the current study unveiled a shared pattern of enhanced glycolysis, depleted OXPHOS and increased ROS synthesis in arthritis development. Glycolysis provides activated cells with ATP and precursors for biosynthesis via influx into PPP5. Inhibition of glycolysis can reduce disease severity of RA mouse models59–61. The upstream regulator analyses on all three transcriptome datasets (Figs. 3e, 6d, 7f) predicted that the key metabolic sensor, SIRT1, was inhibited, while its downstream target NFκB and pro-inflammatory cytokines were activated. This is consistent with the experimental evidence on SIRT1-knockout macrophages, which exhibit hyperacetylated NFKB, higher NFKB-mediated gene transcription and subsequently increased pro-inflammatory cytokine production46. Similarly, treatment of RA macrophages with resveratrol, an unspecific SIRT1 activator, enhanced anti-inflammatory M2 and blocked pro-inflammatory M1 polarization57. These authors confirmed their findings with SIRT1 knockdown in RA macrophages and in bone-marrow derived macrophages from SIRT1 transgenic mice, strengthening a direct role of SIRT1 in macrophage polarization. These mice also showed improved arthritis scores in a CIA model accompanied by an increase in M2 macrophage markers. Similarly, resveratrol improved arthritis scores and reduced incidence in the CIA model—both in preventive and therapeutic mode—by inhibiting Th17 and B cell function62. Furthermore, a recent study also identified gene polymorphisms of SIRT1 in RA patients63.

NAD+ integrates the mRNA and metabolite changes due to its cofactor role for SIRT1’s enzymatic activity27. We hypothesize that at the start of autoimmunity in RA, macrophages and neutrophils experience a change of their effector functions in the direction of pro-inflammatory activation and tissue destruction (Fig. 8d). The activation of these innate immune cells is accompanied by increased glycolysis that consumes NAD+, decreased OXPHOS that slows regeneration of NAD+ by Complex I, increased ROS production and increased intracellular availability of amino acids. Low NAD+ level causes inhibition of SIRT1, which results in accumulation of HIF1A...
Human RA disease progression

Number of differentially expressed genes

overlap of significant upregulated genes

Gene set enrichment analysis

PCA on human synovium transcriptome

IPA upstream regulator analysis
and activation of NFkB. HIF1A and NFkB pathways further promote glycolysis over OXPHOS, which serves as a positive feedback loop in the manifestation of inflammation. On top of that, our data is in line with the notion that macrophages and neutrophils contribute to synovitis by ROS production in MOFA analysis. Our result further underlines the role of SIRT1 and macrophage metabolism in the development of arthritis.

This study also provides a resource that can be mined for mechanistic investigation of metabolic dysregulation that underlies arthritis development in CIA mouse model. We took the large heterogeneity in arthritis phenotype of these mice into consideration and used a large sample number for the CIA mice. Although validation of the CIA RNA-seq study findings does not yield complete match in terms of magnitude of gene expression changes, this is largely because of the differences in the species, tissue types and sequencing protocols. Also, we acknowledge that single-cell RNA-seq on mouse synovium would have provided more comprehensive gene expression at individual cell level, but this approach would have been technically challenging to apply to the tiny size of mouse synovium.

In conclusion, our dynamic analysis of molecular changes on CIA mouse model summarizes the metabolic changes during the development of arthritis. We speculate that activation of SIRT1 and thereby modulation of glycolysis, OXPHOS and ROS metabolism would yield beneficial effect in treatment of RA. We also delivered a comprehensive time-resolved plasma metabolome and paw transcriptome for further pursuit of causal implication in immunometabolism.

Methods

Collagen-induced arthritis (CIA) in mice. All animal experiments were performed in compliance with German animal welfare legislation implementing Directive 63/2010/EU, approved by the Regional Council (Regierungspräsidium Darmstadt) of the state of Hessen, Darmstadt, Germany and carried out in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International accredited facility. Reporting of the animal experiments followed the recommendations in the ARRIVE guidelines.

The study was designed to allow longitudinal analysis of progressive development of arthritis elicited by anti-collagen antibodies 2 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 7 weeks, 8 weeks, and 10 weeks after immunization.

A total of 192 male DBA/1 mice (age 10 to 12 weeks at start of the study, sourced from ENVIGO) were randomized to 8 groups based on their body weights using the BioSTAT Rando software package. Out of the 24 mice per group, 18 were immunized with type II collagen and 6 mice received no immunization to serve as non-diseased controls. The control animals received the same amount of handling, i.e. regular scoring of arthritis score. The sample size was estimated using BioConductor RNASeqSampleSize package and took into account a 20% dropout rate of mice which would not develop arthritis signs and symptoms despite being immunized with type II collagen.

Immunization emulsion was prepared from chicken type II collagen (CII, MD Bioproducts) and Complete Freund’s adjuvant (CFA, Sigma) in an ice-cold water bath. The mice were intradermally injected with 50 μl of this emulsion (containing 100 μg CII) at the base of the tail (day 0). On day 21 animals were boosted with 50 μl Freund’s adjuvant (CFA, Sigma) in an ice-cold water bath. The mice were intradermally injected with 50 μl of this emulsion containing 100 μg CII at the base of the tail (day 0). On day 21 animals were boosted with 50 μl emulsion of CII in Incomplete Freund’s adjuvant (IFA, Sigma).

The arthritis severity in CIA mice was scored in all four paws at 3 times per week for in total 10 weeks. The severity was scored as follows: 0—no clinical signs of arthritis; 1—visible swelling limited to wrists and ankles; 2—visible swelling expanded to the pads with slight redness; 3—visible swelling with heavy redness and ankylosis. The groups were stratified for the two personnel in charge with the scoring, such that in each group both personnel scored half of the mice each.

Tissue collections were done at 9 different time points during the experiment, where age matched male DBA/1 mice (controls) were sacrificed at the same time as the CIA mice. At sacrifice, animals were exsanguinated by cardiac puncture in deep isoflurane anesthesia, and subsequently cervically dislocated. Blood was collected into EDTA-coated micro sample tubes (Sarstedt) after cardiac puncture. Plasma was extracted after centrifugation at 1530×g for 15 min at 4 °C and stored at −80 °C. Mouse paws were cut and snap frozen in liquid nitrogen. The spleen was weighted fresh.

Animals were excluded from analysis only if they had to be removed from the study for humane reason according to the predefined animal welfare stopping criteria. This was the case for one animal each for the 2, 4, and 7 week groups, and 2 animals each for the 8 and 10 week groups. Sample sizes are reported in Suppl. Table 1.
**Human macrophage differentiation and stimulation.** Whole blood samples from healthy volunteers were taken in the Sanofi internal blood donation service located in Frankfurt, Germany. Healthy volunteers signed an informed consent prior to blood donation and signed an individual risk assessment sheet prior to each donation. The blood donation was conducted under the supervision of Dr. Klaus Flechsenhar (Sanofi). The local internal blood donation service was previously approved by the Sanofi-Aventis Deutschland GmbH legal department for R&D and data protection office (Frankfurt, Germany) to fulfill the federal data protection act in Germany. All methods were carried out in accordance with relevant guidelines and regulations (Declaration of Helsinki).

Human peripheral blood monocytes were isolated from anonymous donors’ whole blood using Ficoll density centrifugation, followed by magnetic separation with positive selection (CD14 MicroBeads, Miltenyi Biotec). Monocytes were differentiated into macrophages by culturing in macrophage serum-free medium (Life Technologies) containing 50 ng/ml recombinant human macrophage colony-stimulating factor (Immunotools) for 5 days. Following differentiation, cells were cultured in RPMI 1640 medium supplemented with 10% heat inactivated fetal bovine serum (Thermo Fisher) and maintained at 37 °C in a 5% CO2/air environment. Macrophages were stimulated with 50 ng/ml lipopolysaccharides from *Escherichia coli* O111:B4 (Sigma) for 24 h.

**Figure 8.** Metabolic reprogramming in early RA. (a–c) Differential gene expression of major metabolic genes in the RNA-seq studies of CIA mouse paws, LPS-stimulated human macrophages, and human RA synovium biopsies. Significance was decided by cutoffs of FDR < 0.05 and fold change > 1.5 in up or down direction. (d) Schematic hypothesis showing that innate immune cells drive the metabolic changes by SIRT1 axis at the initial phase of RA.
Luminex assays. Mouse magnetic Luminex assays (R&D Systems) were performed on EDTA mouse plasma according to the manufacturer’s instructions. Beads were read on a Luminex MAGPIX Instrument using the xPONENT software (Luminex Corporation).

Sample preparation for untargeted metabolomics with ultrahigh performance liquid chromatography-tandem mass spectroscopy (UPLC-MS/MS) on mouse plasma. Untargeted metabolomics on mouse plasma was performed at Metabolon Inc. (Morrisville, NC, USA) with a previously published protocol65. Briefly, sample extraction was performed using the automated MicroLab STAR system from Hamilton Company; where 500 µl of 100% methanol was added to 100 µl of plasma sample. Several recovery standards were added prior to the first step in the extraction process for QC purposes. The plasma/methanol mixture was shaken vigorously for 2 min (Glen Mills GenoGrinder 2000) followed by centrifugation for 10 min at 680×g.

The resulting extract was divided into five fractions: two for analysis by two separate reverse phase (RP)/UPLC-MS/MS methods with positive ion mode electrospray ionization (ESI), one for analysis by RP/UPLC-MS/MS with negative ion mode ESI, one for analysis by HILIC/UPLC-MS/MS with negative ion mode ESI, and one sample was reserved for backup. Samples were placed briefly on a TurboVap (Zymark) to remove the organic solvent. The sample extracts were stored overnight under nitrogen before reconstitution.

Instrument analysis of untargeted metabolomics platforms. The sample extract was reconstituted in solvents compatible to each of the four methods as specified below. Each reconstitution solvent also contained a series of additional internal standards at fixed concentrations to ensure injection and chromatographic consistency65. All methods utilized a Waters ACQUITY ultra-performance liquid chromatography (UPLC) and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer operated at 35,000 mass resolution. The detailed chromatography conditions and the method settings for each mass spectrometry method have been published in Supplemental Tables 1 and 2 of the original protocol65 by Metabolon Inc. and briefly described below.

One aliquot was analyzed using acidic positive ion conditions, chromatographically optimized for more hydrophilic compounds. In this method, the extract was reconstituted with 0.05% perfluoropentanoic acid (PFPA) and 0.1% formic acid (FA) in water, and gradient eluted from a C18 column (Waters UPLC BEH C18 — 2.1 × 100 mm, 1.7 µm) using water and methanol, containing 0.05% PFPA and 0.1% FA.

Another aliquot was also analyzed using acidic positive ion conditions, however it was chromatographically optimized for more hydrophobic compounds. In this method, the extract was reconstituted with 1:9 water: isopropyl alcohol (0.05% PFPA and 0.1% FA) and gradient eluted from the same aforementioned C18 column using methanol, acetonitrile, water, 0.05% PFPA and 0.01% FA, operating at an overall higher organic content.

Another aliquot was analyzed using basic negative ion optimized conditions using a separate dedicated C18 column. The basic extracts were reconstituted with 6.5 mM ammonium bicarbonate in water and gradient eluted from the column using methanol and water, however with 6.5 mM ammonium bicarbonate at pH 8.

The fourth aliquot was reconstituted with 2:8 acetonitrile:water (10 mM ammonium formate, pH ~ 10.6). The extract was analyzed via negative ionization following elution from a HILIC column (Waters UPLC BEH Amide 2.1 x 150 mm, 1.7 µm) using a gradient consisting of water and acetonitrile with 10 mM ammonium formate, pH 10.8. The MS analysis alternated between MS and data-dependent MSn scans using dynamic exclusion. The scan range varied slightly between methods but covered 70–1000 m/z. Raw data files are archived and extracted as described below.

Several types of controls were analyzed in concert with the experimental samples: a pooled matrix sample generated by taking a small volume of each experimental sample (or alternatively, use of a pool of well-characterized human plasma) served as a technical replicate throughout the data set; extracted water samples served as process blanks; and a cocktail of QC standards that were carefully chosen not to interfere with the measurement of endogenous compounds were spiked into every analyzed sample, allowed instrument performance monitoring and aided chromatographic alignment. Instrument variability was determined by calculating the median relative standard deviation (RSD) for the standards that were added to each sample prior to injection into the mass spectrometers. Overall process variability was determined by calculating the median RSD for all endogenous metabolites (i.e., non-instrument standards) present in 100% of the pooled matrix samples.

Untargeted metabolomics data extraction and compound identification. Raw data was extracted, peak-identified and QC processed using Metabolon’s hardware and software. Metabolon maintains a library based on authenticated standards that contains the retention time/index (RI), mass to charge ratio (m/z), and chromatographic data (including MS/MS spectral data) on all molecules present in the library. Furthermore, Metabolon’s identifications are based on the detection of a peak (area-under-the-curve of 10 ppm XIC at specific retention index) with three criteria: retention index within a narrow RI window of the proposed identification, accurate mass match to the library ± 10 ppm, and the MS/MS forward and reverse scores between the experimental data and authentic standards. The MS/MS scores are based on a comparison of the ions present in the experimental spectrum to the ions present in the library spectrum. Additional mass spectral entries have been created for structurally unnamed biochemicals, which have been identified by virtue of their recurrent nature (both chromatographic and mass spectral). Library matches for each compound were checked for each sample and corrected if necessary. This study generated an untargeted metabolomics dataset that comprises a total of 929 biochemicals, 815 compounds of known identity and 114 compounds of unknown structural identity. Relative quantification of peaks was done using area-under-the-curve (AUC). While the quantitation of the analyte is based on the AUC of the most predominant ion (usually the molecular ion), we do account for the other ion features that we know to be associated with the specific compound.
For studies spanning multiple days, a data normalization step was performed to correct variation resulting from instrument inter-day tuning differences. Essentially, each compound was corrected in run-day blocks by registering the medians to equal one (1.0) and normalizing each data point proportionately.

**Statistical analysis on untargeted metabolomics of mouse plasma.** Following log transformation, two-way ANOVA using base R package (v4.0.0) was performed to identify metabolites exhibiting significant differences between treatment groups (CIA vs. controls) and time points. All reported significant results on untargeted metabolomics have adjusted p-value cutoff < 0.05 after using False Discovery Rate (FDR) method to correct for multiple testing. PCA was performed using the corresponding function in MetaboAnalystR 3.0.

**Tissue MALDI-MS imaging (tMSI) on mouse paws.** For MALDI-MS imaging experiments 10 µm thick paw cryosections were cut with a cryostat (CM 1950 cryostat, Leica Biosystems), thaw-mounted onto conductive indium thin oxide coated glass slides (ITO, Bruker Daltonik) and subsequently desiccated at room temperature overnight until matrix application or stored at −80 °C under vacuum until further use. MALDI matrix application was performed as previously described. Briefly, 2.5 DHB matrix was dissolved at a concentration of 60 mg/ml in ACN/ddH2O/TFA (50/50/0.2, v/v/v). Matrix deposition onto the tissue was performed by spray coating using a SunCollect sprayer (SunChrom), by using 5 cycles in ascending orders (10, 15, 20, 25, 25 µl/min) at a velocity speed of 300 mm/min. Data acquisition was performed on a 7T Scinax MRMS Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer (Bruker Daltonik) equipped with a dual ESI/MALDI ion source and a Smartbeam II Nd:YAG Laser (355 nm) under the acquisition control of FTMS Control 2.3.0. Images were acquired in the positive ion mode in the m/z range of 100 to 2000 using 2Ω and 2 M magnitude mode with a resolving power of ~400,000 at m/z 400 and a free induction decay of 0.8 ms using FlexImaging 5.0 (Bruker Daltonik) by applying 250 laser shots per measurement position at a lateral resolution of 50 µm. To ensure high mass accuracy an internal lock mass calibration was performed on known DHB ion clusters (m/z 273.03936).

For ion image visualization and statistical evaluation, raw data were loaded and processed using SCiLS Lab MVS (Version 9.01.12514, Bruker Daltonik). Normalization of signal intensities were performed using the total ion count (TIC) normalization and a global peak assignment was performed at a frequency of 1% for data reduction. Reduced data were exported into imzml data format using SCiLS Lab and a peak picking based on the SPUTNIK R package was applied to filter spatial relevant m/z information. The spatial filtered m/z list was mapped against Sanofi’s internal biomarker database at a mass accuracy of 1.2 ppm (1.2 ppm reflects mean ± 2 SD of technical variability over the entire mass range). The intensities values of assigned m/z biomarker candidates were exported from SCiLS Lab as Arb.U and used for statistical evaluation.

Two-way ANOVA with Tukey multiple pairwise-comparisons using base R package (v4.0.0) was applied to calculate adjusted p-values. PCA was performed using the corresponding function in MetaboAnalystR 3.0.

**RNA extraction.** For mouse paws, frozen tissues were homogenized in 1.2 ml of QIAzol Lysis Reagent (Qia-gen) per sample using a TissueLyser (Qiagen) for 2 × 5 min at 30 Hz, 4 °C. The lysates were centrifuged for 5 min at 12,000×g, 4 °C to remove debris. 250 µl of supernatant was used for RNA isolation using the Direct-zol-96 RNA kit (Zymo Research) by following the manufacturer’s instructions. For human macrophages, frozen cell pellet from each well was lysed by addition of 350 µl of the TRI Reagent solution included in the Direct-zol-96 RNA kit. Total RNA was then isolated from the lysates using the Direct-zol-96 RNA kit. The concentration of RNA samples was measured using the Quant-iT RNA Assay Kit (Invitrogen). The RNA quality (RIN) was measured using the RNA kit. Total RNA was then isolated from the lysates using the Direct-zol-96 RNA kit. The concentration of RNA samples was measured using the Quant-iT RNA Assay Kit (Invitrogen). The RNA quality (RIN) was measured using the RNA kit.

**Bulk RNA sequencing.** For mouse paws, 1 µg of total RNA was used as an input material for library preparation using NEBNext Ultra II Directional RNA Library Prep Kit for Illumina with NEBNext Poly(A) mRNA Magnetic Isolation Module (New England Biolabs). The libraries were multiplexed and paired-end sequenced (2 × 75 bp) on NextSeq 550 instrument (Illumina) using the NextSeq 500/550 High Output Kit (150 cycles). The average sequencing depth is 8.9 million reads per mouse paw sample.

For mouse macrophages, 60 ng of total RNA was used for library preparation using NEBNext Ultra II Directional RNA Library Prep Kit for Illumina with NEBNext RNA Depletion Kit (New England Biolabs). The libraries were paired-end sequenced (2 × 75 bp) on NovaSeq 6000 instrument (Illumina) using the NovaSeq 6000 S2 Reagent Kit (200 cycles). The average sequencing depth is 36.4 million reads per human macrophage sample.

**RNA-seq data pre-processing.** FASTQ files generated by sequencing mouse paws were pre-processed by RNA-Seq Analysis Snapemake Workflow (RASflow). Briefly, raw read quality was evaluated using FastQC. Reads were trimmed for adaptors and sequence quality using Trim Galore. Trimmed reads were aligned to mouse GRCh39 reference genome using HISAT2 and reads were counted by using featureCounts.

FASTQ files generated by sequencing human macrophages were imported into ArrayStudio (Qiagen). Briefly, raw data quality control was performed and then a filtering step was applied to remove reads corresponding to rRNAs as well as reads having low quality score or shorter than 25 nt. Reads were further mapped to the Human genome B38 using Omicsoft sequence aligner (OSA, version 4) and quantified using Ensembl.B96 gene model. Paired reads were counted at the gene level.

For the public RNA-seq dataset on human synovial biopsies (GSE89408), raw counts at the gene level were extracted from HumanDisease_B38_GC33 of DiseaseLand (Qiagen). Briefly, DiseaseLand contains curated publicly available RNA-seq and expression array data, where all samples have been processed through the same pipeline to allow for cross project comparison. For HumanDisease_B38_GC33, alignment of FASTQ files was
done using OSA to Human genome B38. The average sequencing depth is 34.1 million reads per human synovial sample.

**Statistical analysis on RNA-seq data.** The statistical test on RNA-seq raw count data was performed by DESeq2. Depending on the respective study design and sequencing depth, genes that have > 1 CPM (counts per million) in at least 20% of the mouse samples, at least 30% of the human macrophage samples, or at least 5% of the human synovium samples were included for analysis. For data on mouse samples, a time series differential analysis was done by the likelihood ratio test (LRT) in DESeq2, whereas for data on human macrophages and synovium (GSE89408), Wald test was used. The p-values attained by hypothesis testing in DESeq2 were corrected for multiple testing using the FDR method. Significant differentially expressed genes were defined by cutoffs of FDR < 0.05 and fold change > 1.5 in up or down direction. Genes that cannot be mapped to Entrez IDs, like novel pseudogenes, were removed from the list of differentially expressed genes. Furthermore, variance stabilizing transformation (VST) was applied to count data prior to PCA, and then the top 500 most variable genes were subjected to prcomp function (PCA) in the default stats package in R (v4.0.0).

**Gene set enrichment analysis.** Gene set enrichment analysis was performed with the up-to-date biological process gene sets from the Gene Ontology database using fgsea. Genes were ranked in a decreasing order according to their fold changes, or to their loadings in a MOFA factor, and this ranking was used as the input to fgsea. By default, 1000 permutations were done to calculate statistical significance. FDR-corrected p-value below 0.05 was considered as significant for a gene set.

**MOFA model training.** MOFA model training was done on 171 mouse subjects that were profiled with both paw transcriptome and plasma metabolomics using MOFA2 package. Gene-level RNA-seq counts were pre-filtered and VST transformed using DESeq2. Metabolite intensities were log transformed. The inputs of MOFA model training comprised of the top 500 most variable genes and all 929 metabolites. Package default values were used for the training parameters, except for num_factors = 25, drop_factor_threshold = 0.02 and convergence_mode = slow. The latent factors and feature loadings were extracted from the best trained model with build-in functions of MOFA2.

**IPA upstream regulator analysis.** Ingenuity Pathway Analysis (IPA, Qiagen) was used for prediction of upstream regulators from sets of identified differentially expressed genes from RNA-seq studies. The overlap p-values were calculated by the right-tailed Fisher's exact test, and B–H adjusted for multiple testing.

**Western blot.** Frozen joints were covered with ice-cold NP-40 Cell Lysis Buffer (Invitrogen) supplemented with 1x complete protease inhibitor cocktail (Roche) and 1 mM PMSF. Samples were homogenized with 7 mm steel beads in the TissueLyser II (Qiagen). 10–30 µg lysate was separated on a NuPAGE 4–12% Bis–Tris, 1.0 mm, Midi Protein Gel (Invitrogen) by SDS-PAGE at 130 V, subsequently blotted on a nitrocellulose membrane from iBlot system (Invitrogen) and incubated with TBS blocking buffer (LI-COR, 927-60001) for 1 h at RT. Odyssey protein molecular weight marker (LI-COR, 928-40000) was used for molecular weight sizing. The blots were physically cut at 25 kDa before incubating with primary antibodies overnight at 4 °C. The primary antibodies include c-Myc Mouse mAb (Invitrogen, 13–2500, 1:200 dilution) and MCT1 Mouse polyclonal (abcam, ab45134, 1:1000 dilution) for loading control. After overnight incubations, IRDye® 680RD Goat anti-Mouse IgG (LI-COR, 926-68070, 1:15000 dilution) was introduced for 1 h at RT.

Afterwards, the blots were cut at 100 kDa and the middle part was incubated with Hsp60 rabbit antibody (abcam, ab45134, 1:1000 dilution) for loading control. After overnight incubations, IRDye® 800RD Goat anti-Rabbit IgG (LI-COR, 926-68070, 1:15000 dilution) was introduced for 1 h at RT.

For image acquisition by Odyssey infrared imager (LI-COR), first a preliminary and low-resolution image was captured in the defined area of the blot. Afterwards, we adjusted the scan area around the molecular weight of the protein targets and the visible band and re-scanned for a high-resolution image for analysis. Signals were quantified with the Image Studio ver2.0 software (LI-COR).

**Other statistical analyses.** For the associations between mouse groups (CIA, control) and phenotype features (scores, spleen weights, concentrations of cytokine or chemokine), two-tail Welch t tests was used. For the associations between mouse scores and factor values, one-way ANOVA was used. Both tests were done using base R package (v4.0.0).

**Visualization.** The plots that depict study data and statistics were created with ggplot2, heatmap or ggVennDiagram. The schematic plots were created with BioRender.com.

**Data availability**

The RNA sequencing data on CIA mouse paws and LPS-stimulated human macrophages have been deposited at Gene Expression Omnibus (GEO) database, under the accession numbers GSE193335 and GSE193336 respectively.

**Code availability**

The codes generated during the study are available from the corresponding author on reasonable request.
References

1. Smolen, J. S. et al. Rheumatoid arthritis. Nat. Rev. Dis. Primers 4(1), 18001 (2018).
2. van der Woude, D. & van der Helm-van, A. H. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 32(1), 174–187 (2018).
3. Lewis, M. J. et al. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Rep. 28(9), 2435–2470.e5 (2019).
4. Makowski, L., Chaib, M. & Rathmell, J. C. Immunometabolism: From basic mechanisms to translation. Immunol. Rev. 295(1), 5–14 (2020).
5. Ganeshan, K. & Chawla, A. Metabolic regulation of immune responses. Annu. Rev. Immunol. 32(1), 609–634 (2014).
6. Angajala, A. et al. Diverse roles of mitochondria in immune responses: Novel insights into immuno-metabolism. Front. Immunol. 9, 1605 (2018).
7. Chaudhuri, A. J. et al. High-resolution 18F-FDG PET with MRI for monitoring response to treatment in rheumatoid arthritis. Eur. J. Nucl. Med. Mol. Imaging 37(5), 1047–1047 (2010).
8. Garcia-Carbonell, R. et al. Critical role of glucose metabolism in rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Rheumatol. 68(7), 1614–1626 (2016).
9. Zezina, E. et al. Glucose transporter 1 in rheumatoid arthritis and autoimmunity. Wiley Interdiscip. Rev. Syst. Biol. Med. 12(4), e1483 (2020).
10. Umar, S. et al. IRAK4 inhibitor mitigates inflammation by rebalancing metabolism malfunction in RA macrophages and fibroblasts. Life Sci. 287, 120114 (2021).
11. Koedderitzsch, K. et al. TNF induces glycolytic shift in fibroblast like synoviocytes via GLUT1 and HIF1A. Sci. Rep. 11(1), 19385 (2021).
12. Onodera, Y. et al. Reactive oxygen species induce Cox-2 expression via TAK1 activation in synovial fibroblast cells. FEBs Open Bio 5, 492–501 (2015).
13. Ng, C. T. et al. Synovial tissue hypoxia and inflammation in vivo. Ann. Rheum. Dis. 69(7), 1389–1395 (2010).
14. Binnieca, M. et al. Oxidative damage in synovial tissue is associated with in vivo hypoxic status in the arthritic joint. Ann. Rheum. Dis. 69(6), 1172–1178 (2010).
15. Holmdahl, R. et al. The molecular pathogenesis of collagen-induced arthritis in mice—A model for rheumatoid arthritis. Ageing Res. Rev. 11(1), 135–147 (2002).
16. Holmdahl, R., Malmström, V. & Burkhardt, H. Autoimmune priming, tissue attack and chronic inflammation—The three stages of rheumatoid arthritis. Eur. J. Immunol. 44(6), 1593–1599 (2014).
17. Burkhardt, H. et al. Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthrithogenic in collagen-induced arthritis in the mouse. Arthritis Rheum. 46(9), 2339–2348 (2002).
18. Kim, H.-Y. et al. Enhanced T cell proliferative response to type II collagen and synthetic peptide C3J (225–274) in patients with rheumatoid arthritis. Arthritis Rheum. 42(10), 2085–2093 (1999).
19. Corthay, A. et al. Epitope glycosylation plays a critical role for T cell recognition of type II collagen in rheumatoid arthritis. Eur. J. Immunol. 28(8), 2580–2590 (1998).
20. Kiyoi, T. Histological analysis of arthritic joints. In Rheumatoid Arthritis: Methods and Protocols (ed. Liu, S.) 29–39 (Springer, 2018).
21. Pietrosimone, K. M. et al. Collagen-induced arthritis: A model for murine autoimmunity. Bio-Protec. 5(20), e1625 (2015).
22. Brand, D. D., Latham, K. A. & Rosloniec, E. Collagen-induced arthritis. Nat. Protoc. 2(5), 1269–1275 (2007).
23. Marc Feldmann, A., Brennan, F. M. & Maini, R. N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14(1), 397–440 (1996).
24. Meister, A. On the enzymology of amino acid transport. Science 180(4081), 33–39 (1973).
25. Bhusu, S. & Sharma, M. What does serum γ-glutamyltransferase tell us as a cardiometabolic risk marker? Ann. Clin. Biochem. 53(3), 312–332 (2016).
26. Perricone, C., De Carolis, C. & Perricone, R. Glutathione: A key player in autoimmunity. Autoimmun. Rev. 8(6), 697–701 (2009).
27. Xie, N. et al. NAD+ metabolism: Pathophysiologic mechanisms and therapeutic potential. Signal Transduct. Target. Ther. 5(1), 227 (2020).
28. Preiss, J. & Handler, P. Biosynthesis of diphosphopyridine nucleotide: I. Identification of intermediates. J. Biol. Chem. 233(2), 488–492 (1958).
29. Preiss, J. & Handler, P. Biosynthesis of diphosphopyridine nucleotide II. Enzymatic aspects. J. Biol. Chem. 233(2), 493–500 (1958).
30. Strelko, C. L. & Handler, P. Iaconic acid is a mammalian metabolite induced during macrophage activation. J. Am. Chem. Soc. 133(41), 16386–16389 (2011).
31. Ashburner, M. et al. Gene Ontology: Tool for the unification of biology. Nat. Genet. 25(1), 25–29 (2000).
32. Murphy, M. P. How mitochondria produce reactive oxygen species. Biochem. J. 417(1), 1–13 (2008).
33. Krämer, A. et al. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 30(4), 523–530 (2013).
34. Ral, P. et al. IRGM1 links mitochondrial quality control to autoimmunity. Nat. Immunol. 22(3), 312–321 (2021).
35. Guarente, L. Sirtuins in aging and disease. In Cold Spring Harbor Symposium on Quantitative Biology (Cold Spring Harbor Laboratory Press, 2007).
36. Schug, T. T. et al. Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. Mol. Cell. Biol. 30(19), 4712–4721 (2010).
37. Argelaguet, R. et al. Multiomics factor analysis—A framework for unsupervised integration of multi-omics data sets. Mol. Syst. Biol. 14(6), e8124 (2018).
38. Mei, J. et al. CXCL5 regulates chemokine scavenging and pulmonary host defense to bacterial infection. Immunity 33(1), 106–117 (2010).
39. Tchetverikov, I. et al. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann. Rheum. Dis. 63(7), 881–883 (2004).
40. Sumbayev, V. V. LPS-induced Toll-like receptor 4 signalling triggers cross-talk of apoptosis signal-regulating kinase 1 (ASK1) and HIF-1a protein. FEBS Lett. 582(2), 319–326 (2008).
41. Yu, Q. et al. SIRT1 and HIF1a signaling in metabolism and immune responses. Cancer Lett. 418, 20–26 (2018).
42. Guo, Y. et al. CD40L-dependent pathway is active at various stages of rheumatoid arthritis disease progression. J. Immunol. 198(11), 4490–4501 (2017).
43. Eiserich, J. P. et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 391(6665), 393–397 (1998).
44. Papayannopoulos, V. et al. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J. Cell Biol. 191(3), 677–691 (2010).
45. Khandpur, R. et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci. Transl. Med. 5(178), 178 (2013).
46. Panday, A. et al. NADPH oxidases: An overview from structure to innate immunity-associated pathologies. Cell. Mol. Immunol. 12(1), 5–23 (2015).
47. Lim, J.-H. et al. Siruin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1a. Mol. Cell 38(6), 864–878 (2010).
48. Cramer, T. et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 112(5), 645–657 (2003).
49. Yuan, J., Minter-Dykhouse, K. & Lou, Z. A c-Myc–SIRT1 feedback loop regulates cell growth and transformation. J. Cell Biol. 185(2), 203–211 (2009).
50. Wu, R. et al. ACOD1 in immunometabolism and disease. Cell. Mol. Immunol. 17(8), 822–833 (2020).
51. O’Neil, L. J. & Kaplan, M. J. Neutrophils in rheumatoid arthritis: Breaking immune tolerance and fueling disease. Trends Mol. Med. 25(3), 215–227 (2019).
52. Tak, P. P. & Bresnihan, B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: Advances from synovial biopsy and tissue analysis. Arthritis Rheum. 43(12), 2619–2633 (2000).
53. Zhang, F. et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat. Immunol. 20(7), 928–942 (2019).
54. Norberg, B., Bjelle, A. & Eriksson, S. Joint fluid leukocytosis of patients with rheumatoid arthritis evidence for neutrophil and monocyte chemotaxis in vivo. Clin. Rheumatol. 2(3), 237–242 (1983).
55. Mulherin, D., Fitzgerald, O. & Bresnihan, B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum. 39(1), 115–124 (1996).
56. Sasaki, C. et al. Metabolomic approach to the exploration of biomarkers associated with disease activity in rheumatoid arthritis. PlOS ONE 14(7), e0219400 (2019).
57. Michopoulos, F. et al. Targeted metabolic profiling of the Tg197 mouse model reveals itaconic acid as a marker of rheumatoid arthritis. J. Proteome Res. 15(12), 4579–4590 (2016).
58. Daly, R. et al. Changes in plasma inacutaneous elevation in early rheumatoid arthritis patients elucidates disease activity associated macrophage activation. Metabolites 10(6), 241 (2020).
59. Abbadou, G. et al. Inhibition of glycolysis reduces disease severity in an autoimmune model of rheumatoid arthritis. Front. Immunol. 9, 1973 (2018).
60. Mangal, J. J. et al. Inhibition of glycolysis in the presence of antigen generates suppressive antigen-specific responses and restrains rheumatoid arthritis in mice. Biomaterials 277, 121079 (2021).
61. Umar, S. et al. Metabolic regulation of RA macrophages is distinct from RA fibroblasts and blockade of glycolysis alleviates inflammatory phenotype in both cell types. Cell. Mol. Life Sci. 78(23), 7693–7707 (2021).
62. Park, S. Y. et al. SIRT1/adenosine monophosphate-activated protein kinase alpha signaling enhances macrophage polarization to an anti-inflammatory phenotype in rheumatoid arthritis. Front. Immunol. 8, 1135 (2017).
63. Xuzhu, G. et al. Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann. Rheum. Dis. 71(1), 129–135 (2012).
64. Zou, J. et al. Gene polymorphisms of SIRT1 in patients with rheumatoid arthritis. Int. J. Rheum. Dis. 25, 210 (2021).
65. Ford, L. et al. Precision of a clinical metabolomics profiling platform for use in the identification of inborn errors of metabolism. J. Appl. Lab. Med. 5(2), 342–356 (2020).
66. R Core Team, R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, 2020).
67. Pang, Z. et al. MetaBioAnalyst R 3.0: Toward an optimized workflow for global metabolomics. Metabolites 10(5), 186 (2020).
68. Hinsenkamp, I. et al. Inhibition of rho-associated kinase 1/2 attenuates tumor growth in murine gastric cancer. Neoplasia 18(8), 900–911 (2016).
69. Inglese, P. et al. SPUDTNIK: An R package for filtering of spatially related peaks in mass spectrometry imaging data. Bioinformatics 35(1), 178–180 (2018).
70. Zhang, X. & Jonassen, I. RASflow: An RNA-Seq analysis workflow with Snakemake. BMC Bioinform. 21(1), 110 (2020).
71. Andrews, S. FastQC: A Quality Control Tool for High Throughput Sequence Data. https://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (2010).
72. Krueger, F. Trim Galore. https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/ (2012).
73. Kim, D., Langmead, B. & Salzberg, S. L. HISAT: A fast spliced aligner with low memory requirements. Nat. Methods 12(4), 357–360 (2015).
74. Xiao, Y., Smyth, G. K. & Shi, W. featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30(7), 923–930 (2014).
75. Hu, J. et al. OSA: A fast and accurate alignment tool for RNA-Seq. Bioinformatics 28(14), 1933–1934 (2012).
76. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15(12), 530 (2014).
77. Bergshoeffe, A. A. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. BioRxiv. https://doi.org/10.1101/060012 (2016).
78. Angelgetu, R. et al. MOFA+: A statistical framework for comprehensive integration of multi-modal single-cell data. Genome Biol. 21(1), 111 (2020).
79. Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer, 2016).
80. Kohle, P. Pheatmap: Pretty Heatmaps [Software]. https://cran.r-project.org/web/packages/pheatmap/ (2015).
81. Gao, C.-H., Yu, G. & Cai, P. ggVennDiagram: An intuitive, easy-to-use, and highly customizable R package to generate venn diagram. Front. Genet. 12, 1598 (2021).

Acknowledgements

The authors thank members of the Type 1/17 Immunology Cluster in Sanofi for technical support on the mouse experiments and Constanze Holz (Sanofi DMPK-Metabolism/tMSI) for technical support on the tissue MALDI-MS imaging. We are grateful to Annick Pleraux (Sanofi Biomarker Statistics) and Stephanie Pierson (Sanofi Pasteur/Digital R&D/Bioinformatics) for implementing the RASflow pipeline on the enterprise cloud computing environment. The authors thank Sandrine Tolou (Sanofi Translational Sciences) for the support on RNA sequencing of human macrophages and Mark Magid (Sanofi Precision Oncology) for depositing sequencing data into GEO database.

Author contributions

N.B., C.A. and L.L. conceived and designed research studies. L.L., J.F., B.M., B.W., E.Z., G.T. and M.D. performed the experiments. L.L. and C.R. did the bioinformatic analyses. L.L. and N.B. wrote the manuscript, and all authors revised it. N.B. provided supervision and is the guarantor of this work.
Competing interests
All authors are current or former employees of Sanofi and may hold shares and/or stock options in the company.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-16005-9.

Correspondence and requests for materials should be addressed to N.B.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022